Steris Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Steris Plc on May 3, 2023. The filing reports a corporate governance event involving the expansion of the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a prorated director fee of $74,220 for the remainder of the 2022-23 term, payable in career restricted stock units.
Material Changes
The Board of Directors increased its size from nine to ten members effective May 3, 2023. Dr. Esther Alegria was elected as a new director. Dr. Alegria brings experience as the Founder and CEO of APIE Therapeutics and former Senior Vice President of Global Manufacturing at Biogen, Inc.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. It strictly addresses the appointment of a new director and the associated compensatory arrangements.
Key Facts for Investor Verification
- Dr. Esther Alegria was elected to the Board of Directors effective May 3, 2023.
- The Board size increased from nine to ten members.
- Dr. Alegria's compensation for the remainder of the term is $74,220 in restricted stock units.
- Dr. Alegria has prior board experience with AVID Bioservices, Inc.
- No financial results or operational updates are included in this specific filing.